Aging and Disease

www.aginganddisease.org

Volume 13, Number 3; 852-867, June 2022

http://dx.doi.org/10.14336/AD.2021.1110

Review

Stem Cell-derived Exosomal MicroRNA as Therapy for Vascular Age-related Diseases

Hang Ren, Ziyuan Guo, Yang Liu, Chunli Song*

Department of Cardiovascular Internal Medicine, the Second Hospital of Jilin University, Changchun, China

Accepted August 25, 2021; Revised November 9, 2021; Accepted November 10, 2021

ABSTRACT: Vascular age-related diseases describe a group of age-related chronic diseases that result in a considerable healthcare burden to society. Vascular aging includes structural changes and dysfunctions of endothelial cells (ECs) and smooth muscle cells (SMCs) in blood vessels. Compared with conventional treatment for vascular age-related diseases, stem cell (SC) therapy elicits better anti-aging effects via the inhibition/delay of ECs and SMCs from entering senescence. Exosomal noncoding RNA (ncRNAs) in vascular aging and stem cell-derived exosomal microRNAs (SCEV-miRNAs), especially in mesenchymal stem cells, have an important role in the development of age-related diseases. This review summarizes SCEV-miRNAs of diverse origins that may play a vital role in treating subclinical and clinical stages of vascular age-related disorders. We further explored possible age-related pathways and molecular targets of SCEV-miRNA, which are associated with dysfunctions of ECs and SMCs in the senescent stage. Moreover, the perspectives and difficulties of SCEV-miRNA clinical translation are discussed. This review aims to provide greater understanding of the biology of vascular aging and to identify critical therapeutic targets for SCEV-miRNAs. Though still in its infancy, the potential value of SCEV-miRNAs for vascular age-related diseases is clear.

Key words: MicroRNAs, senescence, stem cell-derived exosomal microRNA, vascular age-related diseases

1. Introduction

There is increasing evidence that most major vascular diseases are interconnected with the biology of aging [1]. Vascular age-related disorders mainly affect the cardiovascular, cerebrovascular, and peripheral vascular systems, causing coronary artery disease (CAD), hypertension, and stroke (Fig. 1). However, the specific mechanisms that are involved in vascular aging are multifactorial and unclear. Treatments for vascular age-related diseases, including pharmacotherapy, structured exercise, and lifestyle modification, have been widely used to treat vascular-age related diseases. However, adverse side effects have been reported during pharmacotherapy. For example, rapamycin may cause metabolic disorders, and metformin may cause gastrointestinal disorders [2]. Given the increasing aging population, it is crucial to understand the molecular mechanisms underlying vascular aging and explore more efficient therapeutic strategies (Fig. 2). Although still in its initial stage, SCEV-miRNA therapy in vascular age-related diseases has shown significant potential therapeutic and clinical application. We briefly summarized the current studies regarding the therapeutic role of SCEV-miRNAs in vascular age-related diseases and clarified their possible age-dependent molecular or pathways downstream.

2. Aging and health

Aging is a significant healthcare challenge for China. By 2050, an estimated 400 million Chinese citizens will be aged > 65 years, 150 million of whom will be > 80 years

*Correspondence should be addressed to: Dr. Chunli Song, Department of Cardiovascular Internal Medicine, the Second Hospital of Jilin University, Nanguan District, Changchun 130041, Jilin, China. E-mail: 2632494613@qq.com.

Copyright: © 2022 Ren H. et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Aging is the primary driver for most chronic diseases [3]. As vascular aging is a specific type of organic aging, new therapeutic approaches for vascular aging are urgently needed. For instance, anti-aging molecules, such as nicotinamide adenine dinucleotide (NAD+), may be promising therapeutic targets as interventional strategies [4, 5]. Vascular aging can be reversed by the impairment of the endothelial NAD+-H₂S signaling network [6]. Using NAD+ augmentation, the accelerated aging in Werner syndrome, a classical premature aging disease, is limited [7].

Figure 1. Vascular aging mainly includes age-related to cardiovascular, cerebrovascular, and peripheral vascular diseases. Vascular aging may be caused by the dysfunction of endothelial and smooth muscle cells (SMCs), which includes abnormal proliferation, inflammation, migration, apoptosis, and angiogenesis.

3. EC and SMC senescence

As endothelial cells (EC) and smooth muscle cells (SMC) are the main components of the inner and middle layers of the vascular wall, respectively, their structural and functional dysfunctions are the leading causes of vascular aging, primarily characterized by age-related phenotypes, such as abnormal proliferation, inflammation, migration, angiogenesis, and apoptosis [8]. Healthy ECs maintain a balance between vascular vasodilation and contraction, proinflammatory and anti-inflammatory activities, as well as thrombotic and antithrombotic activities. With vascular aging, ECs lose this ability [9]. Healthy SMCs display a contractile phenotype that regulates the blood vessel’s structure and function. Vascular aging induces phenotypic alterations in SMCs, which function in arterial calcification and atherosclerosis [10].

Senescent vascular cells communicate with their neighbors via direct cell-to-cell contact and indirect secretory factor-dependent signaling and the altered senescence-associated secretory phenotype (SASP). These events diminish stem cell (SC) regeneration and accelerate vascular aging [11, 12]. Biological effects accompanying senescence-associated risk factors, such as hypertension, hyperglycemia, hyperlipidemia, obesity, smoking, environmental pollutants or toxin exposure, and sedentary lifestyles, have become more pronounced, resulting in EC and SMC senescence and further causing vascular aging diseases (Fig. 2).

4. SCEV-miRNA in vascular aging

Stem cells are broadly defined as self-renewing precursor cells with the ability to differentiate into various cell types. SC depletion is an essential mechanism of vascular
aging [13]. As cell therapy, SC supplementation can enhance the stemness of dormant cells and their anti-senescence properties [14], delaying or even reversing aging in vivo [15]. However, some issues, such as low survival rates after transplantation, tumorigenicity, immunogenicity, low tissue-targeting effects, and ethical concerns limit their clinical applications [16-19].

Extracellular vesicles (EVs) are lipid bilayer-containing particles released from cells, both in physiological and pathological conditions [20]. Stem cell-derived extracellular vesicles (SCEVs) retain the anti-aging characteristics [21] and avoid tumorigenesis and immune rejection of SCs [22]. As therapeutic gene vectors, SCEVs are less immunogenic than nanoparticles and less toxic compared with adenoviruses. Additionally, they can cross the blood-brain barrier (BBB) and other biological barriers and are easier to store and transport than other gene vectors [22-24].

As a crucial functional cargo of EVs, microRNAs (miRNAs) are small noncoding RNA molecules of approximately 22 nucleotides [25]. They mainly engage the 3'-untranslated region (UTR) of the target mRNA followed by the initiation of target degradation or inhibition of translation. They participate in the epigenetic regulation of vascular age-related dysfunctions. The
majority of senescence-inducing signals engage either or both of the p53/p21 and p16/pRb pathways as the final effectors of the cellular senescence program [26]. Most senescence-regulatory miRNAs, such as micro34a and micro106a, have been further confirmed to regulate p53/p21 and p16/pRb pathways signaling pathways either directly or indirectly. However, there is still little information regarding the potential involvement of miRNAs in modulating the complex process of cellular senescence. Some other miRNAs have a demonstrated link to the complex senescence regulatory networks, causing further vascular aging phenotypes, but with no significant evidence on their relevance to the two aforementioned classic pathways [26].

Table 1. Identified senescence-related SCEV-miRNA, their possible direct pathways/targets downstream and altered senescence-related cellular phenotypes.

| SCEV-miRNAs | Possible direct pathways/ targets | Altered senescence-related cellular phenotypes | Ref. |
|-------------|----------------------------------|-----------------------------------------------|------|
| miR-199b-5p | Jagger-1/Notch1 pathway           | √ Proliferation                               | [1]  |
| miR-21, miR-21-5p, miR-221-3p | PTEN/AKT pathway | √ Migration                                    | [2-4]|
| miR-218     | Ribo-1                           | √ Apoptosis                                    | [5]  |
| miR-181b-5p | TRPM7                            | √ Angiogenesis                                 | [6]  |
| miR-512-3p  | Keap1                            | √                                             | [7]  |
| miR-145     | JAM-A                            | √                                             | [8]  |
| miR-342-5p  | PPP1R12B                         | √                                             | [9]  |
| miR-210     | Efn3                             | √                                             | [10] |
| miR-132     | RasGAP                          | √                                             | [11] |
| miR-210     | nSMase2                          | √                                             | [12] |
| miR-204, miR-17 superfamily | STAT3 pathway | √                                             | [13] |
| miR-292, miR-103, miR-17, miR-210 | Profibrotic gene                        | √                                             | [14] |
| miR-125a    | DLL4                             | √                                             | [15] |
| miR-21-5p  | THBS1                            | √                                             | [16] |
| miR-126     | SPRED1                           | √                                             | [17] |
| miR-132-3p  | RASA1                            | √                                             | [18] |

SCEV-miRNA, a combination of gene and cell therapy, is associated with the senescence process. For example, aging speed is controlled partly through hypothalamic stem cell-derived exosomal miRNAs. Mechanistically, hypothalamic stem/progenitor cells contribute significantly to exosomal miRNAs in the cerebrospinal fluid, and the level of these exosomal miRNAs declines during aging. In contrast, treatment with healthy hypothalamic stem/progenitor cell-secreted exosomes slows aging [27]. Exogenous therapy comprising SCEV-miRNAs may regulate age-related dysfunctions and further cure vascular age-related diseases through the pathways/targets mentioned above. We summarized some recently identified SCEV-miRNAs related to vascular cellular senescence, their pathways and targets downstream, and altered senescence phenotypes of EC and SMC in Table 1.

Notably, the possible therapeutic modulatory effect of SCEV-miRNA on EC angiogenesis is also essential for wound healing, tissue repair, and cancer development, which do not belong to vascular age-related diseases. Related research that does not mention specific vascular age-related diseases was excluded for clarity [28, 29]. Considering its potent anti-aging effects and prospects, SCEV-miRNA therapy for vascular age-related diseases, which targets ECs and SMCs [30, 31] (Fig. 3 and Fig. 4). SCEV-miRNAs regulate the mRNA expression that are involved in senescence-related dysfunctions including abnormal inflammation, apoptosis, proliferation, migration, and angiogenesis. The mesenchymal stem cell (MSC)-derived exosomal miR-17 superfamily, which include miR-126, and miR-132-3p, regulate inflammation-related mRNAs, such as signal transducer and activator of transcription 3 (STAT3), high-mobility group box 1 protein (HMGB1), RAS, and PI3K, respectively [32-34] (Fig. 3A). The MSC-derived exosomal miR-132-3p, miR-210, and miR-21, regulate apoptosis-related mRNAs, which include RasGAP-120 [35], neutral type II sphingomyelinase (nSMase2) [36], and phosphatase and tensin homolog/protein kinase B (PTEN/AKT) [37], respectively (Fig. 3B). The induced pluripotent stem cell (iPSC)-derived exosomal miR-199-5p regulate cell proliferation, migration, and angiogenesis by targeting the Jagger-1/Notch 1 pathway [38]. MSC-derived exosomal miR-221-3p and endothelial progenitor cell (EPC)-derived exosomal miR-21-5p regulate the
proliferation, migration, and angiogenesis of ECs by targeting PTEN/AKT [39, 40]. Adipose tissue-derived stem cell (ADSC)-derived exosomal miR-191 regulates proliferation-related BMPR2 [41] (Fig. 3C). The renal artery-derived vascular progenitor cell (RAPC)-derived exosomal miR-218, ADSC-derived exosomal miR-181b-5p, and MSC-derived exosomal miR-145 regulate migration-related mRNAs, Ribo-1 [42], vascular endothelial growth factor (VEGF) [43], and junction adhesion molecule A (JAM-A) [44] respectively (Fig. 3D). The MSC- and cardiac progenitor cell (CPC)-derived exosomal miR-132 regulates angiogenesis-related RasGAP-120 [35]. MSC-derived exosomal miR-204 regulates angiogenesis-related STAT3 [32]. ADSC-derived exosomal miR-125a and miR-181b-5p regulate delta-like 4(DLL4) [28] and VEGF [43], respectively. The MSC, EPC, and CD34+ stem cell-derived exosomal miR-126 regulate angiogenesis-related sprouty-related EVH1 domain-containing protein 1(SPRD1) [33] (Fig. 3E). Meanwhile, SCEV-miRNAs also act on SMCs by regulating the mRNA expression of genes that participate in senescence-related dysfunctions. The senescence-related calcification response of SMCs can be altered by 63 specific miRNAs [45] and miR-146a of MSC-derived exosomes (MSC-EXOs) by targeting the TXNIP [46]. The senescence-related inflammation response can be altered by the miR-23b-3p in MSC-EXOs [47]. The senescence-related proliferation response can be altered by the miR-126 and miR-145 in MSC-EXOs [48] (Fig. 4).

Figure 3. Role of SCEV-miRNAs in EC senescence. Extracellular microRNAs derived from stem cells (SCEV-miRNAs) act on endothelial cells (ECs), by regulating mRNA expression of genes involved in senescence-related dysfunctions, including abnormal inflammation, apoptosis, proliferation, migration, and angiogenesis.

5. SCEV-miRNAs as therapy for vascular age-related diseases

The course of vascular age-related diseases can be divided into subclinical and clinical stages. The subclinical stage mainly refers to age-related pathological changes, such as vascular calcification and atherosclerosis. The clinical setting mainly pertains to age-related cardiovascular, cerebrovascular, and peripheral vascular diseases. Next, we summarized the current progress in SCEV-miRNA therapy at the subclinical and clinical stages of vascular age-related disorders from the perspective of clinical applications.

5.1 SCEV-miRNAs and the subclinical stage of vascular age-related diseases

Vascular calcification refers to the deposition of ectopic calcium salts in blood vessels caused by abnormal calcium and phosphorus metabolism. It is an essential pathological phenotype associated with vascular aging. The cytological basis of vascular calcification originates from the differentiation of vascular SMCs (VSMCs) into cells with an osteoblast-like phenotype and is regulated by various miRNAs [49]. Mounting evidence suggests that SCEV-miRNAs may pose an anti-calcification function (Table 2). During osteogenic differentiation, exosomal miRNAs isolated from MSCs were profiled using miRNA arrays. Among 79 miRNAs detected, nine exosomal
miRNAs were upregulated, and four miRNAs were downregulated. Five miRNAs (miR-199b, miR-218, miR-148a, miR-135b, and miR-221) were further validated and differentially expressed at different time points indicating their potential anti-aging therapeutic effects [50]. Beyond that, miR-146a, an overexpressed replicative senescent EC, is involved in important cell functions (growth, proliferation, death, survival, and maintenance) and age-related diseases (cancer, skeletal and muscle disorders, neurological, cardiovascular, and metabolic diseases). MiR-146 participates in the regulation of vascular aging partly through modulating mitochondrial integrity and function in aging cells, and by inducing or contributing to the inflammatory response and age-related diseases [31]. MiR-146a expression in MSC-derived exosomes (MSC-EXOs) significantly increases after stimulation with advanced glycation end products (TXNIP). TXNIP regulates cellular senescence by inhibiting the AKT pathways via direct interactions under conditions of metabolic stress [46, 51]. After stimulation with high phosphorus levels, 63 exosomal miRNAs derived from bone marrow-derived mesenchymal stem cells (BMSCs) were found to be significantly upregulated, which inhibited high phosphorus-induced calcification in human aortic VSMCs. MiRNAs activate the mechanistic target of rapamycin (mTOR), mitogen-activated protein kinase (MAPK), and Wnt signaling pathways, which are regulatory pathways of aging, and thus alleviate age-related vascular calcification [2, 45]. Research regarding SCEVs is progressing towards the pre-clinical stage with increasing attention focused on MSC-derived EVs [48, 52]. For example, vascular grafts often exhibit low patency rates within patients after surgery. When a graft functionalized by MSC-derived EVs was applied to hyperlipidemic rats, the results showed that incorporating MSC-derived EVs inhibited vascular thrombosis and calcification, enhancing graft patency. Furthermore, miR-126 and miR-145 were shown to be enriched in MSC-EXOs [48, 52]. The age-related anti-calcification effect of MSC-EXOs is attributable to the presence of these miRNAs, which inhibit endothelial dysfunction and regulate cellular replicative senescence. Related studies provide a necessary theoretical basis for the clinical applications of these findings to coronary artery bypass grafting, thrombosis, and vascular calcification [48].

Figure 4. Role of SCEV-miRNAs in SMC senescence. Extracellular microRNAs derived from stem cells (SCEV-miRNAs) act on smooth muscle cells (SMCs), regulating senescence-related cellular phenotypes, including abnormal inflammation, apoptosis, proliferation, migration, and angiogenesis.

Atherosclerosis is a vital pathology that is associated with vascular aging and characterized by intimal plaques and cholesterol accumulation in the arterial wall. These changes result in arterial wall stiffness and stenosis. We found that the transfer of miRNA-221 from MSC-EVs inhibits atherosclerotic plaque formation [53]. Atherosclerotic plaques contain aged ECs and SMCs [54, 55]. Additionally, senescent cells accumulate during aging and contribute to the pathogenesis of atherosclerosis, as well as other age-related disorders and chronic diseases. Apolipoprotein E-deficient mice fed a high-fat diet (HFD) also presented signs of senescent ECs in their blood vessels, eventually leading to atherosclerosis [56]. The removal of senescent cells via “senolysis” has been reported to reduce atherogenesis [57]. Vascular cellular dysfunction contributes to the alterations in extracellular matrix (ECM) proteins, resulting in vascular stiffness and loss of elasticity, and the proinflammatory state promotes atherosclerosis. The possibility of preventing accelerated cellular senescence is a therapeutic target in atherosclerosis [55]. SCEV-miRNAs can be used to treat age-related atherosclerosis...
(Table 2). For example, miR-342-5p, differentially expressed in healthy individuals and patients with atherosclerosis, promotes EC apoptosis via mitochondrial-related pathways [58]. PPP1R1Z2B, a target gene of miR-342-5p related to VSMC contraction and oxytocin signaling, promotes the occurrence and development of atherosclerosis. In a model of atherosclerosis, reduced expression of miR-342-5p in ADSC-derived EV targets PPP1R1Z2B to combat aging-associated atherosclerosis [58]. In addition, SCEV-miRNAs inhibit the formation or reduce the size of plaques. For example, increased levels of miR-145 in mesenchymal SC-derived extracellular vesicles (MSC-EVs) inhibit the formation or rupture of plaques in CAD patients by downregulating JAM-A [44]. MiR-512-3p, enriched in MSC-EXOs, markedly inhibits ox-LDL-mediated EC dysfunction, accelerates cell proliferation, inhibits apoptosis, and suppresses the levels of inflammatory cytokines by targeting Kelch-like ECH-associated protein 1 (Keap1) [59].

Table 2. SCEV-miRNAs associated with the subclinical stage of vascular aging diseases.

| Process | Stem cells | Recipient cells | Exosomal cargo | Targeted or pathways | Senescence-related cell functions | Ref. |
|---------|------------|----------------|----------------|----------------------|-----------------------------------|------|
| Calcification | MSCs | VSMCs | 63 miRNAs identified | Wnt, mTOR, MAPK | Anti-calcification | [19] |
| Calcification | MSCs | VSMCs | miR-146a | 3’ UTR of TXNIP gene | Anti-calcification | [20] |
| Calcification | MSCs | ECs/VSMCs | miR-126, miR-145 | —— | Anti-calcification, promotes proliferation | [21] |
| AS | MSCs | ECs | miR-145 | Downregulates JAM-A | Anti-migration | [8] |
| AS | ADSCs | ECs | miR-342-5p | PPP1R1Z2B | Anti-apoptosis | [9] |
| AS | MSCs | ECs | miR-512-3p | regulating Keap1 | Promotes proliferation, anti-apoptosis Anti-inflammation | [7] |

5.2 SCEV-miRNAs and the clinical stage of vascular age-related diseases

5.2.1 SCEV-miRNAs and cardiovascular age-related diseases

Vascular aging, a regressive change, is a leading cause of cardiovascular diseases [60]. SCEV-miRNAs inhibit fibrosis and promote angiogenesis of infarcted regions by regulating cellular dysfunction of vascular aging. The therapeutic effect depends on the type of SC, tissue of origin, donor age, and cell microenvironment (Table 3). MiRNAs, protein cargo, and biological effects of EVs vary by SC type. For example, MSC-EVs contain high amounts of miR-23b, miR-124a, miR-126, and miR-221, promote angiogenesis, and inhibit apoptosis and fibrosis in vascular aging. In addition, MSC-EVs exert antitumor, anti-insulin resistance, and immunoregulatory effects. Furthermore, as donor cells for heart transplantation, CPCs can improve cardiac function and promote cardiovascular formation through CPC-EVs [61]. The elevated expression of miR-132 in CPC-EVs after myocardial infarction is related to cellular senescence and stemness [62]. The miR-132-induced downregulation of RasGAP-p120 improves collateral circulation in the infarcted area by promoting angiogenesis [35, 63]. Recent study has confirmed miR-132 as a target for heart failure (HF) therapy, with anti-miR-132 treatments having considerable clinical potential [64]. Differentially expressed during aging, miR-103 and miR-17 might induce the reverse regulation of aging-associated pathways [65]. MiR-103-3p is associated with the regulation of reduced cardiac apoptosis and promotes cardiac repair through the GSK3β/β-catenin pathway in acute myocardial infarction (AMI) [66], while miR-17-5p-mediated endoplasmic reticulum stress promotes AMI [67]. MiR-210 expression is also altered in age-related cardiovascular diseases such as atherosclerosis, acute myocardial infarction, and heart failure [68]. Circulating miR-210 concentrations are increased in patients with HF [69]. The levels of miR-103, miR-17, and miR-210 are elevated in CPC-EVs under hypoxic conditions, promoting angiogenesis and inhibiting fibrosis [70]. Finally, cardiosphere-derived cells are also the donor cells for cardiovascular age-related diseases [71]. Donor cells impact the therapeutic effect of SCEV-miRNAs. MSCs derived from the endometrium exert a more substantial paracrine influence and better angiogenic effect than BMSCs and ADSCs. In an AMI rat model, increased expression of miR-21 in endometrium-derived mesenchymal stem cell (EnMSC)-EVs improved clinical prognosis by inhibiting the PTEN/AKT pathway and EC apoptosis and by promoting angiogenesis [37]. However, downregulated miRNA-21 in MSC-EVs of HF patients increases proliferation and migration and suppresses angiogenesis of ECs [40].
Table 3. SCEV-miRNAs associated with aging-related cardiovascular diseases.

| Process | Stem cells | Recipient cells | Exosomal cargo | Targets or pathways | Senescence-related cell function | Ref. |
|---------|------------|-----------------|----------------|--------------------|----------------------------------|------|
| AMI     | EnMSCs     | ECs             | miR-21         | PTEN/AKT           | Anti-apoptosis, pro-angiogenesis  | [2]  |
| AMI     | MSCs (Young donors, 20–25 years old) | ECs | miR-221-3p | PTEN/AKT | Pro-angiogenesis, anti-fibrosis, pro-proliferation, pro-migration | [3]  |
| AMI     | BM-MSCs    | ECs             | miR-210        | Increase the expression of nSMase2 under hypoxic conditions | Anti-apoptosis, pro-angiogenesis | [12] |
| AMI     | BM-MSCs    | ECs             | miR-210        | Inhibits the expression of Efna3 gene | Pro-angiogenesis, pro-proliferation, pro-migration | [10] |
| AMI     | CDC        | ECs             | miR-12, miR-130a, miR-210 | — | Pro-angiogenesis | [22] |
| AMI     | CPC        | ECs             | miR-132        | Downregulates RasGAP-120 | Pro-angiogenesis | [11] |
| AMI     | CPC        | ECs             | miR-292, miR-210, miR-103, miR-17 | Decreases profibrotic gene expression | Pro-angiogenesis, anti-fibrosis | [14] |
| HF      | Cardiac stromal cells | ECs | miR-21-5p | PTEN/AKT | Pro-proliferation, pro-migration | [4]  |
| HF      | BM-MSCs    | ECs             | 23 miRNAs identified | —  | Anti-apoptosis, pro-angiogenesis | [23] |

The regenerative activity of SCEVs from young donors is more pronounced than that of cells from old donors. Neonatal umbilical cord-produced MSC-EVs contain abundant anti-aging signals and rejuvenate senescent adult BMSCs [72]. For example, miR-221-3p, an anti-aging indicator highly expressed in age-related diseases, is abundant in MCS-EVs from young donors. MiR-221 functions in telomere maintenance and regulates the cell cycle [73] by reducing fibrosis and inhibiting the PTEN/AKT pathway and promoting proliferation, migration, and angiogenesis of ECs [39]. Hence, young donors have high translational value in anti-aging intervention as prominent EV donors for vascular age-related diseases.

The therapeutic effects of SCEV-miRNAs depend on their microenvironment. For example, the paracrine effect of MSCs is potentiated by ischemia-hypoxia. EV biogenesis is regulated by nSMase2 and Rab proteins. nSMase2 expression increases under ischemia-hypoxia, causing more pronounced paracrine and therapeutic effects from SCEV-miRNA. Injecting C57BL/6 AMI mice with MSC-EVs cultured under hypoxic or normoxic conditions revealed that miR-210 expression is elevated in mice that received hypoxic MSC-EVs [36]. MiR-210 is upregulated by hypoxia-inducible factor 1α (HIF1-α) under hypoxic conditions, which results in cell cycle arrest and senescence via inhibition of the E2F transcription factor family [74]. MiR-210 induces chromosomal aberrations, double-stranded DNA breakage, and reactive oxygen species (ROS) accumulation, thereby promoting a senescent phenotype [75]. In cardiovascular age-related diseases, miR-210 promotes angiogenesis and inhibits apoptosis in ECs. Therefore, hypoxic preconditioning of donor cells can optimize the therapeutic effects of SCEV-miRNAs [36]. Intramyocardial injection of MSC-EVs into the left anterior descending coronary artery-infarct zone in murine infarction models resulted in a selective elevation of miR-210 levels, which improved cardiac function after myocardial infarction [76]. In addition, bioactive and chemical pretreatment of donor cells impacts the therapeutic effect of miRNAs.

A network analysis of miRNA-profiled MSC-EXOs was performed to identify the dominant biological processes and pathways modulated by exosomal miRNAs. An analysis of crucial landscape pathways modulated by exosomal miRNAs revealed a significant increase in the levels of 23 specific miRNAs enriched in cardiovascular and angiogenesis processes [77]. By acting on more than 5,000 downstream genes, miRNAs promote angiogenesis and inhibit apoptosis. The anti-vascular aging effect is achieved by the targeted regulation of related miRNAs.
Table 4. SCEV-miRNAs associated with aging-related cerebrovascular diseases.

| Process                        | Stem cells | Recipient cells | Exosomal cargo | Targets or pathways                                                                 | Senescence-related cell functions          | Ref. |
|--------------------------------|------------|-----------------|----------------|--------------------------------------------------------------------------------------|--------------------------------------------|------|
| Ischemic stroke                | ADSCs      | ECs             | miR-181b-5p    | Upregulates HIF-1α and VEGF, downregulates TRPM7 and TIMP3                           | Pro-migration, angiogenesis                | [6]  |
| Ischemic cerebrovascular disease | MSCs      | ECs             | miR-132-3p    | Upregulates RAS and PI3K, downregulates RASA1                                        | Anti-apoptosis                              | [18] |
| Brain ischemic injury          | EPCs       | ECs             | miR-21-5p     | Inhibits THBS1                                                                      | Pro-proliferation, migration, vascular repair | [16] |
| Vascular disease of spinal cord | MSCs      | ECs             | miR-126       | Inhibits SPRED1 and PI3R2 expression                                                  | Pro-angiogenesis                            | [17] |
| Intracranial aneurysm          | BM-MSCs    | VSMCs           | miR-23b-3p    | Suppresses the PI3k/AKT/NF-κB signaling pathway, targets KLF5                        | Anti-inflammatory, improves pathological remodeling of the intracranial aneurysm wall | [24] |

5.2.2. SCEV-miRNAs and cerebrovascular age-related diseases

The term cerebrovascular disease refers to various conditions, including cerebral atherosclerosis, stenosis, occlusion, cerebral artery injury, and cerebral aneurysm. The brain consumes the most oxygen in the human body, and its structure and function are heavily dependent on the blood supply. Vascular aging makes the brain prone to ischemic and hemorrhagic injury with secondary brain atrophy, BBB damage, sensorimotor function, and cognitive decline. Age-related cerebrovascular diseases include stroke, cognitive aging, vascular cognitive impairment, dementia [78], Alzheimer's disease [79], and cerebral aneurysm (Table 4). ECs are an essential component of the neurovascular unit, comprising pericytes, ECs in cerebral vessels, parenchymal brain cells, and intercellular junctions of the BBB [80]. Endothelial aging affects vascular homeostasis, remodeling, and BBB integrity; endothelial dysfunction plays a crucial role in vascular aging [81].

SCEV-miRNAs play a role in age-related cerebrovascular diseases by modulating senescence-related miRNAs. As an essential regulator of endothelial cellular senescence and nerve injury, miRNA expression varies with age. For example, levels of age-related miRNAs, such as miR-34a and miR-29, are altered after stroke. SCEV-miRNA promotes EC proliferation and migration to form a vascular scaffold, inhibiting EC apoptosis from reducing the injury area size. For example, miR-181b expression is elevated in the ECs of the elderly, which is associated with endothelial cell senescence and the regulation of neovascularization [82]. Furthermore, miR-181b-5p is upregulated in ADSC-EVs after stroke [43]. MiR-181b-5p enhances axonal growth and suppresses apoptosis to reduce the infarction area by targeting the suppressor of TRPM7; however, it also upregulates the expression of VEGF, promoting angiogenesis and neurogenesis [43]. Another miRNA, miR-132, is a marker of vascular aging. After cerebral ischemia, miR-132-3p overexpression in MSC-EVs downregulates target protein RASA1 levels. It upregulates the expression of Ras and downstream PI3K phosphorylation, which improves vascular age-related ischemic injury by inhibiting cellular apoptosis [34]. As another example, in a rat model of carotid artery injury, age-related miR-21-5p expression is increased. Overexpression of miR-21-5p promotes age-related dysfunction by inhibiting thrombospondin 1 (THBS1). THBS1 causes vascular dysfunction and ischemia by inducing reactive oxygen species (ROS) production and disrupting vasodilation in the aging coronary artery [83, 84]. Furthermore, miR-126 levels in ECs are related to the stage of aging [85], and the expression of MSC-EV miR-126 increases after spinal cord ischemic injury [33]. By promoting the expression of SPRED1 and phosphoinositide-3-kinase regulatory subunit 2 (PIK3R2), miR-21-5p promotes angiogenesis and nerve regeneration, which improves vascular age-related dysfunction after spinal cord injury in the rat. Finally, the expression of miR-23 downregulates lamin-B1 (LMNB1), which is an essential regulator of aging. Increased expression of miR-23b-3p in MSC-EVs inhibits the inflammatory response. Moreover, it improves age-related remodeling of the intracranial aneurysm wall by inhibiting the PI3K/AKT/NF-κB signaling pathway in SMCs, relieving intracranial aneurysms [47].
5.2.3 SCEV-miRNAs and peripheral vascular age-related diseases

Peripheral artery disease (PAD), pulmonary hypertension (PAH), chronic kidney disease (CKD), and erectile dysfunction are age-related peripheral vascular diseases [86]. An increasing number of studies have focused on the therapeutic effects of SCEV-miRNAs on age-related peripheral vascular diseases (Table 5). The prevalence and incidence of PAD are highly age-related [87]. Beyond atherosclerosis, accelerated vascular aging might form the basis of the pathological manifestations of PAD [88]. MiR-675 is an essential regulator of cellular senescence. Melatonin also attenuates senescence-associated proliferation reductions that antagonize premature CPC senescence via the H19/miR-675/USP10 pathway [89]. MiR-675 participates in the anti-aging pathway of melatonin (MT) in premature cardiac senescence and regulates vascular cell dysfunction by downregulating the TGF-β-1/pSMAD/p21 pathway. Furthermore, aging rats display a down regulation of miR-675. The delivery of miR-675 by SCEVs prevents aging-induced vascular dysfunction in the mouse hind limb. The therapeutic effect of EVs is significantly enhanced by encapsulation in a silk fibroin hydrogel. That study further identified the signaling pathway that mediates aging-induced vascular dysfunction and is the basis for developing an exosome-based therapy to inhibit the aging process [31]. In addition, miR-199b-5p, miR-143-5p, miR-291b, and miR-20b-5p could also be involved in regulating age-related endothelial dysfunction and the prevention of aging. For example, in a mouse model of ischemic limb, miR-199b-5p levels in induced pluripotent stem cell (iPSC)-derived endothelial exosomes were upregulated, inhibiting the Jagged-1/Notch1 signaling, pathway upregulates VEGFR2 and promoting age-related EC migration, proliferation, and angiogenesis [38]. In addition, exosomes derived from induced vascular progenitor cells (iVPCs) promoted angiogenesis, in vitro and in vivo, in a rat hind limb ischemia model. This therapeutic effect of iVPC-EXOs is thought to be related to the expression of age-related exosomal miR-143p, miR-20b-5p, and miR-291b [90].

PAH is characterized by dysfunction of the pulmonary artery endothelium and particularly by excessive proliferation. Pulmonary artery aging is an important cause of PAH associated with age-related pulmonary artery dysfunction. Excessive EC proliferation results in pulmonary vascular remodeling and vascular occlusion, eventually causing end-stage irreversible pulmonary hypertension [91, 92]. According to subclinical studies, SCEV-miRNAs enable the recovery of endothelial function to cure age-related PAH [93]. As previously mentioned, both miR-17 and miR-204 regulate aging [94, 95]. One study showed that the intravenous delivery of MSC-EVs could inhibit age-related PAH in a rat model of hypoxic PAH [93]. Sequence analysis revealed downregulation of the miR-17 superfamily and upregulation of miR-204 levels in ECs. This inhibited the STAT signaling pathway, and thus regulated excessive

### Table 5. SCEV-miRNAs associated with aging-related peripheral vascular diseases.

| Process          | Stem cells | Recipient cells | Exosomal cargo | Targets or pathways | Senescence-related cell functions | Ref. |
|------------------|------------|-----------------|----------------|---------------------|----------------------------------|------|
| PAH              | ADSCs      | ECs             | miR-191        | Regulates BMPR2      | Pro-proliferation                | [25] |
| PAH              | MSCs       | ECs             | miR-204        | STAT3               | Pro-angiogenesis                 | [13] |
| PAH              | MSCs       | ECs             | miR-17 superfamily | Inhibits STAT3      | Anti-inflammation                | [13] |
| PAD              | iPSCs      | ECs             | miR-199b-5p    | Inhibits the Jagged-1/Notch1 signaling, pathway upregulates VEGFR2 | Pro-proliferation, migration, angiogenesis | [1]  |
| PAD              | iVPC       | ECs             | miR-143-3p, miR-291b, miR-20b-5p | Pentraxin-3 and insulin-like growth factor-binding protein-3 | Pro-angiogenesis | [26] |
| PAD              | Cardiac MSC | Ischemic limb   | miR-7116-5p    | Regulates protein ubiquitination | Pro-proliferation | [27] |
| PAD              | Stem cell  | H2C9            | miR-675        | —                   | Anti-senescence                  | [28] |
| Renal injury     | RAPC       | ECs             | miR-218        | Targets Robo1       | Pro-migration                    | [5]  |
| Erectile dysfunction | ADSCs    | ECs             | miR-126, miR-130a, miR-132, miR-let7b, miR-let7c | —                   | Pro-angiogenesis                 | [29] |
|                  | ADSCs      | ECs             | —              | —                   | Anti-fibrosis                    |      |
proliferation and ameliorating of age-related PAH [93]. Furthermore, miR-191, overexpressed in age-related PAH, promotes the proliferation and migration of ECs [32]. The downregulation of miR-191 activates bone morphogenetic protein receptor 2 (BMPR2) mutations by preventing BMPR2 degradation, which inhibits exaggerated inflammatory responses, rescues age-related endothelial dysfunction, and reverses PAH [41, 96].

The characterization of CKD includes a progressive vascular disease with systemic inflammation, muscle wasting, and weakness. Multiple mechanisms might be at play in the pathogenesis of vascular aging in CKD. Cell senescence and SASP-related chronic inflammation play essential roles in this disease. In an experimental mouse model of acute ischemia and hyper-perfusion injury, RAPC-derived exosomes were enriched in miR-218, which is highly expressed in aging mice. This miRNA improves renal function by targeting Robo1 mRNA in ECs and promoting cell migration. Studies have shown the potential of RAPC autologous transplantation for the treatment of vascular age-related diseases [42, 97]. Vascular aging also contributes to erectile dysfunction. ADSC-derived exosomes are rich in pro-angiogenic miRNAs (miR-126, miR-130a, and miR-132) and the anti-fibrotic miRNA family (miR-let7b and miR-let7c), which restore erectile function and reduce cavernous fibrosis [98].

![Figure 5. Extracellular microRNAs derived from stem cells (SCEV-miRNAs) in the treatment of subclinical and clinical vascular aging diseases.](image)

6. Perspectives for clinical translation

Theoretically, the chemically synthesized microRNAs are also reasonable to treat vascular age-related diseases. However, the use of chemically-synthesized miRNA mimics or antagonists is limited by low transfection efficacy or rate-limiting miRNA processing. Several limitations may also hamper their translation into the clinical practice, such as off-target effects, immune stimulation [99]. Whereas there are some advantages in using stem cell-derived microRNAs for the treatment of vascular age-related diseases. For example, many types of anti-aging microRNAs such as miR-146a/b, miR-183, miR-335, miR-128, miR-133a, and miR-155 are contained in the stem cell-derived exosomes [15]. In addition, stem cells can facilitate cell-cell communication via the dynamic release of exosomes. The biological and structural features of exosomes make them especially ideal for exogenous miRNA delivery and more suitable for clinical practice and facilitate trafficking of miRNAs into the site of action [31]. SCEV-miRNA as therapy for vascular age-related diseases has tremendous prospects. However, its clinical application has certain limitations. First, the particular mechanism of vascular aging remains
unclear, which is restrictive for studies. Most studies on SCEV-miRNA are subclinical and have mainly focused on a specific aging disease, such as cancer, stroke, or osteoarthritis; moreover, they are based on the acute phase of the disease [99]. Second, there are concerns regarding the large-scale production of SCEV-miRNA in vitro. SCEVs are heterogeneous with different subgroups and varying cargoes. The expansion, optimal isolation, purification, scaled-up cultivation, efficient release, and subsequent RNA quantification and stability tests of SCEVs should be further explored [100].

Furthermore, the safety of SCEV-miRNA should be assessed carefully before clinical application in vivo. Unmodified exosomes accumulate predominantly in the liver, spleen, and lung, with lower levels detected in target issues [93]. Finally, SCEV-miRNA accounts for a small percentage of exosomal cargo. Rather than a one-to-one intervention, it also regulates vascular age-related phenotypes through complex genetic and epigenetic regulatory networks.

In conclusion, the clinical application of SCEV-miRNAs for vascular age-related diseases is promising (Fig. 5). Although the number of studies is increasing, the exact role of SCEVs in the anti-aging mechanism and regenerative effects remains unclear. Further exploration of the specific molecular mechanisms of SCEV-miRNAs and additional data from pre-clinical and clinical studies are required. Several challenges must be overcome to drive SCEV-miRNAs that suppress vascular age-related diseases towards large-scale production and clinical translation.

Acknowledgments

This work was supported by the 2018 Bethune Plan Research Project of Jilin University (2018BO03) and by the 2019 and 2020 Health Special Projects of Jilin Provincial Department of Finance (2019SCZT008, 2020SCZT018).

Conflicts of interest

The authors declare no conflict of interest.

References

[1] Justice JN, Ferrucci L, Newman AB, Aroda VR, Bahnson JL, Divers J, et al. (2018). A framework for selection of blood-based biomarkers for geroscience-guided clinical trials: report from the TAME Biomarkers Workgroup. Geroscience, 40: 419-436.

[2] Hamczyk MR, Nevada RM, Barettoni A, Fuster V, André V (2020). Biological Versus Chronological Aging: JACC Focus Seminar. J Am Coll Cardiol, 75: 919-930.

[3] Fang EF, Scheibe-Knudsen M, Jahn HJ, Li J, Ling L, Guo H, et al. (2015). A research agenda for aging in China in the 21st century. Ageing Res Rev, 24: 197-205.

[4] Fang EF, Xie C, Schenkell JA, Wu C, Long Q, Cui H, et al. (2020). A research agenda for ageing in China in the 21st century (2nd edition): Focusing on basic and translational research, long-term care, policy and social networks. Ageing Res Rev, 64: 101174.

[5] Fang EF,Tao J (2020). Targeting on the NAD(+) -mitophagy axis to treat cardiovascular disease. Aging Med (Milton), 3: 151-152.

[6] Das A, Huang GX, Bonkowski MS, Longchamp A, Li C, Schultz MB, et al. (2018). Impairment of an Endothelial NAD(+) -H(2)S Signaling Network Is a Reversible Cause of Vascular Aging. Cell, 173: 74-89.e20.

[7] Fang EF, Hou Y, Lautrup S, Jensen MB, Yang B, SenGupta T, et al. (2019). NAD(+) augmentation restores mitophagy and limits accelerated aging in Werner syndrome. Nat Commun, 10: 5284.

[8] Ni YQ, Zhan JK, Liu YS (2020). Roles and mechanisms of MFG-E8 in vascular aging-related diseases. Ageing Res Rev, 64: 101176.

[9] Du S, Ling H, Guo Z, Cao Q, Song C (2021). Roles of exosomal miRNA in vascular aging. Pharmacol Res, 165: 105278.

[10] Jaminon A, Reesink K, Kroon A, Schurgers L (2019). The Role of Vascular Smooth Muscle Cells in Arterial Remodeling: Focus on Calcification-Related Processes. Int J Mol Sci, 20.

[11] Ungvari Z, Tarantini S, Donato AJ, Galvan V, Csiszar A (2018). Mechanisms of Vascular Aging. Circ Res, 123: 849-867.

[12] Donato AJ, Machin DR, Lesniewski LA (2018). Mechanisms of Dysfunction in the Aging Vasculature and Role in Age-Related Disease. Circ Res, 123: 825-848.

[13] López-Otín C, Blasco MA, Partridge L, Serrano M, Kroemer G (2013). The hallmarks of aging. Cell, 153: 1194-217.

[14] Baker M (2007). Stem cells by any other name. Nature, 449: 389.

[15] Ullah M, Ng NN, Concepcion W, Thakor AS (2020). Emerging role of stem cell-derived extracellular microRNAs in age-associated human diseases and in different therapies of longevity. Ageing Res Rev, 57: 100979.

[16] Poulos J (2018). The limited application of stem cells in medicine: a review. Stem Cell Res Ther, 9: 1.

[17] Wang S, Guo L, Ge J, Yu L, Cai T, Tian R, et al. (2015). Excess Integrins Cause Lung Entrapment of Mesenchymal Stem Cells. Stem Cells, 33: 3315-26.

[18] Fennema EM, Tchang LAH, Yuan H, van Blitterswijk CA, Martin I, Scherberich A, et al. (2018). Ectopic bone formation by aggregated mesenchymal stem cells from bone marrow and adipose tissue: A comparative study. J Tissue Eng Regen Med, 12: e150-e158.
[19] Lund RJ, Närvä E, Lahesmaa R (2012). Genetic and epigenetic stability of human pluripotent stem cells. Nat Rev Genet, 13: 732-44.

[20] Jurgieliewicz B, Stice S, Yao Y (2021). Therapeutic Potential of Nucleic Acids when Combined with Extracellular Vesicles. Aging Dis, 12: 1476-1493.

[21] Boulanger CM, Loyer X, Raoutou PE, Amabile N (2017). Extracellular vesicles in coronary artery disease. Nat Rev Cardiol, 14: 259-272.

[22] Lou G, Chen Z, Zheng M, Liu Y (2017). Mesenchymal stem cell-derived exosomes as a new therapeutic strategy for liver diseases. Exp Mol Med, 49: e346.

[23] Cully M (2021). Exosome-based candidates move into the clinic. Nat Rev Drug Discov, 20: 6-7.

[24] Rosová I, Dao M, Capoccia B, Link D, Nolta JA (2008). Hypoxic preconditioning results in increased motility and improved therapeutic potential of human mesenchymal stem cells. Stem Cells, 26: 2173-82.

[25] Ni YQ, Lin X, Zhan JK, Liu YS (2020). Roles and Functions of Exosomal Non-coding RNAs in Vascular Aging. Aging Dis, 11: 164-178.

[26] Liu FJ, Wen T, Liu L (2012). MicroRNAs as a novel cellular senescence regulator. Ageing Res Rev, 11: 41-50.

[27] Zhang Y, Kim MS, Jia B, Yan J, Zuniga-Hertz JP, Han C, et al. (2017). Hypothalamic stem cells control aging speed partly through exosomal miRNAs. Nature, 548: 52-57.

[28] Liang X, Zhang L, Wang S, Han Q, Zhao RC (2016). Exosomes secreted by mesenchymal stem cells promote endothelial cell angiogenesis by transferring miR-125a. J Cell Sci, 129: 2182-9.

[29] Gong M, Yu B, Wang J, Wang Y, Liu M, Paul C, et al. (2017). Mesenchymal stem cells release exosomes that transfer miRNAs to endothelial cells and promote angiogenesis. Oncotarget, 8: 45200-45212.

[30] Xu D, Tahara H (2013). The role of exosomes and microRNAs in senescence and aging. Adv Drug Deliv Rev, 65: 368-75.

[31] Han C, Zhou J, Liu B, Liang C, Pan X, Zhang Y, et al. (2019). Delivery of miR-675 by stem cell-derived exosomes encapsulated in silk fibroin hydrogel prevents aging-induced vascular dysfunction in mouse hindlimb. Mater Sci Eng C Mater Biol Appl, 99: 322-332.

[32] Lee C, Mitsialis SA, Aslam M, Vitali SH, Vergadi E, Konstantinou G, et al. (2012). Exosomes mediate the cytoprotective action of mesenchymal stromal cells on hypoxia-induced pulmonary hypertension. Circulation, 126: 2601-11.

[33] Huang JH, Xu Y, Yin XM, Lin FY (2020). Exosomes Derived from miR-126-modified MSCs Promote Angiogenesis and Neurogenesis and Attenuate Apoptosis after Spinal Cord Injury in Rats. Neuroscience, 424: 133-145.

[34] Pan Q, Kuang X, Cai S, Wang X, Du D, Wang J, et al. (2020). miR-132-3p priming enhances the effects of mesenchymal stromal cell-derived exosomes on ameliorating brain ischemic injury. Stem Cell Res Ther, 11: 260.

[35] Barile L, Lionetti V, Cervio E, Matteucci M, Gherghiceanu M, Popescu LM, et al. (2014). Extracellular vesicles from human cardiac progenitor cells inhibit cardiomyocyte apoptosis and improve cardiac function after myocardial infarction. Cardiovasc Res, 103: 530-41.

[36] Zhu J, Lu K, Zhang N, Zhao Y, Ma Q, Shen J, et al. (2018). Myocardial reparative functions of exosomes from mesenchymal stem cells are enhanced by hypoxia treatment of the cells via transferring microRNA-210 in an nSMase2-dependent way. Artif Cells Nanomed Biotechnol, 46: 1659-1670.

[37] Hong K, Jiang Z, Webster KA, Chen J, Hu H, Zhou Y, et al. (2017). Enhanced cardioprotection by Human Endothelium Mesenchymal Stem Cells Driven by Exosomal MicroRNA-21. Stem Cells Transl Med, 6: 209-222.

[38] Ye M, Ni Q, Qi H, Qian X, Chen J, Guo X, et al. (2019). Exosomes Derived from Human Induced Pluripotent Stem Cells-Endothelia Cells Promotes Postnatal Angiogenesis in Mice Bearing Ischemic Limbs. Int J Biol Sci, 15: 158-168.

[39] Sun L, Zhu W, Zhao P, Zhang J, Lu Y, Zhu Y, et al. (2020). Down-Regulated Exosomal MicroRNA-221-3p Derived From Senescent Mesenchymal Stem Cells Impairs Heart Repair. Front Cell Dev Biol, 8: 263.

[40] Qiao L, Hu S, Liu S, Zhang H, Ma H, Huang K, et al. (2019). microRNA-21-5p dysregulation in exosomes derived from heart failure patients impairs regenerative potential. J Clin Invest, 129: 2237-2250.

[41] Zhang C, Wang P, Mohammed A, Zhou Z, Zhang S, Ni S, et al. (2019). Function of Adipose-Derived Mesenchymal Stem Cells in Monocrotaline-Induced Pulmonary Arterial Hypertension through miR-191 via Regulation of BMPR2. Biomed Res Int, 2019: 2858750.

[42] Pang P, Abbott M, Chang SL, Abdi M, Chauhan N, Mistri M, et al. (2017). Human vascular progenitor cells derived from renal arteries are endothelial-like and assist in the repair of injured renal capillary networks. Kidney Int, 91: 129-143.

[43] Yang Y, Cai Y, Zhang Y, Liu J, Xu Z (2018). Exosomes Secreted by Adipose-Derived Stem Cells Contribute to Angiogenesis of Brain Microvascular Endothelial Cells Following Oxygen-Glucose Deprivation In Vitro. Through MicroRNA-181b/TRPM7 Axis. J Mol Neurosci, 65: 74-83.

[44] Yang W, Yin R, Zhu X, Yang S, Wang J, Zhou Z, et al. (2021). Mesenchymal stem-cell-derived exosomal miR-145 inhibits atherosclerosis by targeting JAM-A. Mol Ther Nucleic Acids, 23: 119-131.

[45] Guo Y, Bao S, Guo W, Diao Z, Wang L, Han X, et al. (2019). Bone marrow mesenchymal stem cell-derived exosomes alleviate high phosphorus-induced vascular smooth muscle cells calcification by modifying microRNA profiles. Funct Integr Genomics, 19: 633-643.

[46] Wang Y, Ma WQ, Zhu Y, Han XQ, Liu N (2018). Exosomes Derived From Mesenchymal Stromal Cells Pretreated With Advanced Glycation End Product-
Bovine Serum Albumin Inhibit Calcification of Vascular Smooth Muscle Cells. Front Endocrinol (Lausanne), 9: 524.

[47] Sun X, Zheng X, Zhang X, Zhang Y, Luo G (2020). Exosomal microRNA-23b-3p from bone marrow mesenchymal stem cells maintains T helper/Treg balance by downregulating the PI3k/Akt/NF-κB signaling pathway in intracranial aneurysm. Brain Res Bull, 165: 305-315.

[48] Wei Y, Wu Y, Zhao R, Zhang K, Midgley AC, Kong D, et al. (2019). MSC-derived sEVs enhance potency and inhibit calcification of synthetic vascular grafts by immunomodulation in a rat model of hyperlipidemia. Biomaterials, 204: 13-24.

[49] Lakatta EG, Levy D (2003). Arterial and cardiac aging: major shareholders in cardiovascular disease enterprises: Part II: the aging heart in health: links to cardiovascular disease. Circulation, 107: 346-54.

[50] Xu JF, Yang GH, Pan XH, Zhang SJ, Zhao C, Qiu BS, et al. (2014). Altered microRNA expression profile in exosomes during osteogenic differentiation of human bone marrow-derived mesenchymal stem cells. PLoS One, 9: e114627.

[51] Huy H, Song HY, Kim MJ, Kim WS, Byun JE, et al. (2018). TXNIP regulates AKT-mediated cellular senescence by direct interaction under glucose-mediated metabolic stress. Aging Cell, 17: e12836.

[52] Alique M, Bodega G, Giannarelli C, Carracedo J, Ramirez R (2019). MicroRNA-126 regulates Hypoxia-Inducible Factor-1α which inhibited migration, proliferation, and angiogenesis in replicative endothelial senescence. Sci Rep, 9: 7381.

[53] Guo Z, Zhao Z, Yang C, Song C (2020). Transfer of microRNA-221 from mesenchymal stem cell-derived extracellular vesicles inhibits atherosclerotic plaque formation. Transl Res, 226: 83-95.

[54] Yin H, Pickering JG (2016). Cellular Senescence and Vascular Disease: Novel Routes to Better Understanding and Therapy. Can J Cardiol, 32: 612-23.

[55] Wang JC, Bennett M (2012). Aging and atherosclerosis: mechanisms, functional consequences, and potential therapeutics for cellular senescence. Circ Res, 111: 245-59.

[56] Yang G, Lei Y, Inoue A, Piao L, Hu L, Jiang H, et al. (2017). Exenatide mitigated diet-induced vascular aging and atherosclerotic plaque growth in ApoE-deficient mice under chronic stress. Atherosclerosis, 264: 1-10.

[57] Garrido AM, Kaistha A, Uryga AK, Oc S, Foote K, Shah A, et al. (2021). Efficacy and limitations of senolysis in atherosclerosis. Cardiovasc Res.

[58] Xing X, Li Z, Yang X, Li M, Liu C, Pang Y, et al. (2020). Adipose-derived mesenchymal stem cells-derived exosome-mediated microRNA-342-5p protects endothelial cells against atherosclerosis. Aging (Albany NY), 12: 3880-3898.

[59] Chen S, Zhou H, Zhang B, Hu Q (2021). Exosomal miR-512-3p derived from mesenchymal stem cells inhibits oxidized low-density lipoprotein-induced vascular endothelial cells dysfunction via regulating Keap1. J Biochem Mol Toxicol, 35: 1-11.

[60] Madonna R, Van Laake LW, Davidson SM, Engel FB, Hausenloy DJ, Lecour S, et al. (2016). Position Paper of the European Society of Cardiology Working Group Cellular Biology of the Heart: cell-based therapies for myocardial repair and regeneration in ischemic heart disease and heart failure. Eur Heart J, 37: 1789-98.

[61] Wang L, Jia Q, Xinnong C, Xie Y, Yang Y, Zhang A, et al. (2019). Role of cardiac progenitor cell-derived exosome-mediated microRNA-210 in cardiovascular disease. J Cell Mol Med, 23: 7124-7131.

[62] Mehta A, Zhao JL, Sinha N, Marinov GK, Mann M, Kowalezyk MS, et al. (2015). The MicroRNA-132 and MicroRNA-212 Cluster Regulates Hematopoietic Stem Cell Maintenance and Survival with Age by Buffering FOXO3 Expression. Immunity, 42: 1021-32.

[63] Katre R, Riu F, Mitchell K, Gubernator M, Campagnolo P, Cui Y, et al. (2011). Transplantation of human pericyte progenitor cells improves the repair of infarcted heart through activation of an angiogenic program involving micro-RNA-132. Circ Res, 109: 894-906.

[64] Foinquinos A, Batkai S, Genschel C, Viereck J, Rump S, Gyöngyösi M, et al. (2020). Preclinical development of a miR-132 inhibitor for heart failure treatment. Nat Commun, 11: 633.

[65] Kim JH, Lee BR, Choi ES, Lee KM, Choi SK, Cho JH, et al. (2017). Reverse Expression of Aging-Associated Molecules through Transfection of miRNAs to Aged Mice. Mol Ther Nucleic Acids, 6: 106-115.

[66] Zhu Y, Zhao P, Sun L, Lu Y, Zhu W, Zhang J, et al. (2021). Overexpression of circRNA SNRK targets miR-103-3p to reduce apoptosis and promote cardiac repair through GSK3β/-catenin pathway in rats with myocardial infarction. Cell Death Discov, 7: 84.

[67] Zhao L, Jiang S, Wu N, Shi E, Yang L, Li Q (2021). MiR-17-5p-mediated endoplasmic reticulum stress promotes acute myocardial ischemia injury through targeting Tsg101. Cell Stress Chaperones, 26: 77-90.

[68] Guan Y, Song X, Sun W, Wang Y, Liu B (2019). Effect of Hypoxia-Induced MicroRNA-210 Expression on Cardiovascular Disease and the Underlying Mechanism. Oxid Med Cell Longev, 2019: 4727283.

[69] Rutkovskiy A, Lyngbakken MN, Dahl MB, Bye A, Pedersen MH, Wisloff U, et al. (2021). Circulating MicroRNA-210 Concentrations in Patients with Acute Heart Failure: Data from the Akershus Cardiac Examination 2 Study. Clin Chem, 67: 889-898.

[70] Gray WD, French KM, Ghosh-Choudhary S, Maxwell JT, Brown ME, Platt MO, et al. (2015). Identification of therapeutic covariant microRNA clusters in hypoxia-treated cardiac progenitor cell exosomes using systems biology. Circ Res, 116: 255-63.

[71] Namazi H, Mohit E, Namazi I, Rajabi S, Samadian A, Hajizadeh-Saffar E, et al. (2018). Exosomes secreted by hypoxic cardiosphere-derived cells enhance tube formation and increase pro-angiogenic miRNA. J Cell Biochem, 119: 4150-4160.
[72] Lei Q, Gao F, Liu T, Ren W, Chen L, Cao Y, et al. (2021). Extracellular vesicles deposit PCNA to rejuvenate aged bone marrow-derived mesenchymal stem cells and slow age-related degeneration. Sci Transl Med, 13.

[73] Gerasymchuk M, Cherkasova V, Kovalchuk O, Kovalchuk I (2020). The Role of microRNAs in Organismal and Skin Aging. Int J Mol Sci, 21.

[74] Chen WY, Liu WJ, Zhao YP, Zhou L, Zhang TP, Chen G, et al. (2012). Induction, modulation and potential targets of miR-210 in pancreatic cancer cells. Hepatobiiliary Pancreat Dis Int, 11: 319-24.

[75] Faraonio R, Salerno P, Passaro F, Sedia C, Iaccio A, Bellelli R, et al. (2012). A set of miRNAs participates in the cellular senescence program in human diploid fibroblasts. Cell Death Differ, 19: 713-21.

[76] Wang N, Chen C, Yang D, Liao Q, Luo H, Wang X, et al. (2017). Mesenchymal stem cells-derived extracellular vesicles, via miR-210, improve infarcted cardiac function by promotion of angiogenesis. Biochim Biophys Acta Mol Basis Dis, 1863: 2085-2092.

[77] Ferguson SW, Wang J, Lee CJ, Liu M, Neelamegham S, Canty JM, et al. (2018). The microRNA regulatory landscape of MSC-derived exosomes: a systems view. Sci Rep, 8: 1419.

[78] Yang T, Sun Y, Lu Z, Leak RK, Zhang F (2017). The impact of cerebrovascular aging on vascular cognitive impairment and dementia. Ageing Res Rev, 34: 15-29.

[79] Cortes-Canteli M, Iadecola C (2020). Alzheimer’s Disease and Vascular Aging: JACC Focus Seminar. J Am Coll Cardiol, 75: 942-951.

[80] Netto JP, Iliff J, Stanimirovic D, Varallyay C, et al. (2018). Neurovascular Unit: Basic and Clinical Imaging with Emphasis on Advantages of Ferumoxytol. Neurorsurgery, 82: 770-780.

[81] Miceli V, Russelli G, Iannolo G, Gallo A, Lo Re V, Agnese V, et al. (2020). Role of non-coding RNAs in age-related vascular cognitive impairment: An overview on diagnostic/prognostic value in Vascular Dementia and Vascular Parkinsonism. Mech Ageing Dev, 191: 111332.

[82] Menghini R, Casagrande V, Cardellini M, Martelli E, Terrinoni A, Amati F, et al. (2009). MicroRNA 217 modulates endothelial cell senescence via silent information regulator 1. Circulation, 120: 1524-32.

[83] Hu H, Wang B, Jiang C, Li R, Zhao J (2019). Endothelial progenitor cell-derived exosomes facilitate vascular endothelial cell repair through shutting miR-21-5p to modulate Thrombospondin-1 expression. Clin Sci (Lond), 133: 1629-1644.

[84] LeBlanc AJ,Kelm NQ (2017). Thrombospondin-1, Free Radicals, and the Coronary Microcirculation: The Aging Conundrum. Antioxid Redox Signal, 27: 785-801.

[85] Olivieri F, Bonafè M, Spazzafumo L, Gobbi M, Prattichizzo F, Recchioni R, et al. (2014). Age- and glycemia-related miR-126-3p levels in plasma and endothelial cells. Aging (Albany NY), 6: 771-87.

[86] Ungvari Z, Tarantini S, Sorond F, Merkely B, Csiszar A (2020). Mechanisms of Vascular Aging, A Geroscience Perspective: JACC Focus Seminar. J Am Coll Cardiol, 75: 931-941.

[87] Criqui MH, Aboyans V (2015). Epidemiology of peripheral artery disease. Circ Res, 116: 1509-26.

[88] Ho CY, Shanahan CM (2016). Medial Arterial Calcification: An Overlooked Player in Peripheral Arterial Disease. Arterioscler Thromb Vase Biol, 36: 1475-82.

[89] Cai B, Ma W, Bi C, Yang F, Zhang L, Han Z, et al. (2016). Long noncoding RNA H19 mediates melatonin inhibition of premature senescence of c-kit(+) cardiac progenitor cells by promoting miR-675. J Pineal Res, 61: 82-95.

[90] Johnson TK, Zhao L, Zhu D, Wang Y, Xiao Y, Oguljahan B, et al. (2019). Exosomes derived from induced vascular progenitor cells promote angiogenesis in vitro and in an in vivo rat hindlimb ischemia model. Am J Physiol Heart Circ Physiol, 317: H765-h776.

[91] van der Feen DE, Bossers GPL, Hagdorn QAJ, Moonen JR, Kurakula K, Szulc M, et al. (2020). Cellular senescence impairs the reversibility of pulmonary arterial hypertension. Sci Transl Med, 12.

[92] Kurakula K, Smolders V, Tura-Ceide O, Jukema JW, Quax PHA, Goumans MJ (2021). Endothelial Dysfunction in Pulmonary Hypertension: Cause or Consequence? Biommedicines, 9.

[93] Imai T, Takahashi Y, Nishikawa M, Kato K, Morishita M, Yamashita T, et al. (2015). Macrophage-dependent clearance of systemically administered B16BL6-derived exosomes from the blood circulation in mice. J Extracell Vesicles, 4: 26238.

[94] Xu F, Zhong JY, Lin X, Shan SK, Guo B, Zheng MH, et al. (2020). Melatonin alleviates vascular calcification and ageing through exosomal miR-204/miR-211 cluster in a paracrine manner. J Pineal Res, 68: e12631.

[95] Dellago H, Bobbili MR, Grillari J (2017). MicroRNA-17-5p: At the Crossroads of Cancer and Aging - A Mini-Review. Gerontology, 63: 20-28.

[96] Hautefort A, Mendes-Ferreira P, Sabourin J, Manaud G, Bertero T, Rucker-Martín C, et al. (2019). Bmpr2 Mutant Rats Develop Pulmonary and Cardiac Characteristics of Pulmonary Arterial Hypertension. Circulation, 139: 932-948.

[97] Lai P, Song Q, Yang C, Li Z, Liu S, Liu B, et al. (2016). Loss of Rictor with aging in osteoblasts promotes age-related bone loss. Cell Death Dis, 7: e2408.

[98] Zhu LL, Huang X, Yu W, Chen H, Chen Y, Dai YT (2018). Transplantation of adipose tissue-derived stem cell-derived exosomes ameliorates erectile function in diabetic rats. Andrologia, 50.

[99] Rahmani A, Saleki K, Javanmehr N, Khodaparast J, Saadat P, Nouri HR (2020). Mesenchymal stem cell-derived extracellular vesicle-based therapies protect against coupled degeneration of the central nervous and vascular systems in stroke. Ageing Res Rev, 62: 101106.
[100] Yao X, Wei W, Wang X, Chenglin L, Björklund M, Ouyang H (2019). Stem cell derived exosomes: microRNA therapy for age-related musculoskeletal disorders. Biomaterials, 224: 119492.